Purpose To investigate the value of multimodal diffusion weighted imaging (DWI) in preoperative evaluation of Ki-67 expression of endometrial carcinoma (EC). Materials and Methods Patients who had undergone pelvic DWI, intravoxel incoherent motion (IVIM), and diffusion kurtosis imaging (DKI) sequence MRI scan before surgery were retrospectively enrolled. Single index model, double index model, and DKI were used for post-processing of the DWI data, and the apparent diffusion coefficient (ADC), real diffusion coefficient (D), pseudo diffusion coefficient (D*), perfusion fraction (f), non-Gaussian mean diffusion kurtosis (MK), mean diffusion coefficient (MD) and anisotropy fraction (FA) were calculated and compared between the Ki-67 high (≥50%) and low (<50%) expression groups. Results Forty-two patients with a median age of 56 (range 37 - 75) years were enrolled, including 15 patients with a high Ki-67 (≥50%) expression and 27 with a low Ki-67 (<50%) expression. The MK (0.91 ± 0.12 vs. 0.76 ± 0.12) was significantly (P<0.05) higher while MD (0.99 ± 0.17 vs. 1.16 ± 0.22), D (0.55 ± 0.06 vs. 0.62 ± 0.08), and f (0.21 vs. 0.28) were significantly (P<0.05) lower in the high than in the low expression group. The combined model of MK, MD, D, and f-values had the largest area under the curve (AUC) value of 0.869 (95% CI: 0.764-0.974), sensitivity 0.733 and specificity 0.852, followed by the MK value with an AUC value 0.827 (95% CI: 0.700-0.954), sensitivity 0.733 and specificity 0.815. Conclusions IVIM and DKI have certain diagnostic values for preoperative evaluation of the EC Ki-67 expression, and the combined model has the highest diagnostic efficiency.

KN026 is a novel bispecific HER2-targeted antibody. Fully humanized, IgG1-like antibody binds to two distinct HER2 epitopes, the same domains as trastuzumab and pertuzumab. Preliminary safety and efficacy results (data as of Aug 18, 2022) were presented at SABCs 2022(PD18-08), showed promising efficacy and tolerability. Herein, we update the 2-year follow-up results. Eligible subjects with recurrent/metastatic breast cancer, HER-2 positive and treatment-naive were enrolled. Subjects received KN026 30 mg/kg combined with docetaxel 75 mg/m2 Q3W until disease progression, unacceptable toxicity, or other reasons. The primary endpoints were ORR and DoR. The secondary endpoints included safety, PFS and OS. As of data cut-off date (Mar 10, 2023), 57 subjects were enrolled, the median age was 52 y (min:30, max:67), 100% were female, and 91.2 % (52/57) were stage IV. The confirmed ORR within 55 evaluable subjects was 76.4% (42/55) and DoR was 24.0m (95% CI 20.27, NE). The median study follow-up was 24.2m (95%CI:22.80, 25.56). The mPFS was 25.4m (95% CI:17.97, NE) and the mOS was not reached. The OS rates at 12m, 24m and 30m were 93.0% (95% CI:82.37, 97.31), 83.7% (95% CI:70.97, 91.19) and 83.7% (95% CI:70.97, 91.19). The mPFS of subjects with or without visceral metastasis were 23.6m and 28.1m. The mPFS of subjects with or without brain metastasis were 13.7m and 25.4m, respectively. The incidence of KN026-related Grade≥3 TRAE was 38.6% (22/57), including neutrophil count decreased 26.3% (15/57), leucopenia 24.6% (14/57), alanine aminotransferase increased 14.0% (8/57) and others less than 10%. The incidence of serious adverse events was 19.3% (11/57), including febrile neutropenia 5.3% (3/57), leucopenia 3.5% (2/57), and others ≤ 2%. There was no KN026 -related death. KN026 in combination with docetaxel is well tolerated and has shown promising clinical benefit as 1L treatment for HER2-positive BC. After 2 years follow-up, mPFS was 25.4m and the 30-m OS rate was 83.7%, which is very promising. Robustness of efficacy and safety results will be further confirmed in an ongoing randomized phase 3 clinical trial with PTH as control.

Ovarian cancer is the most deadly gynecologic malignancy, and its incidence is gradually increasing. Despite improvements after treatment, the results are unsatisfactory and survival rates are relatively low. Therefore, early diagnosis and effective treatment remain two major challenges. Peptides have received significant attention in the search for new diagnostic and therapeutic approaches. Radiolabeled peptides specifically bind to cancer cell surface receptors for diagnostic purposes, while differential peptides in bodily fluids can also be used as new diagnostic markers. In terms of treatment, peptides can exert cytotoxic effects directly or act as ligands for targeted drug delivery. Peptide-based vaccines are an effective approach for tumor immunotherapy and have achieved clinical benefit. In addition, several advantages of peptides, such as specific targeting, low immunogenicity, ease of synthesis and high biosafety, make peptides attractive alternative tools for the diagnosis and treatment of cancer, particularly ovarian cancer. In this review, we focus on the recent research progress regarding peptides in the diagnosis and treatment of ovarian cancer, and their potential applications in the clinical setting.

Ovarian cancer is one of the most common female tumors all over the world, and its mortality rate ranks first among gynecological malignancies. A progressive assessment, diagnosis and remedy are significant for the proper management of the disease process. In this paper, a prompt, non-invasive and highly effective screening test for ovarian cancer was developed based on the Raman spectroscopy (RS) data of fresh ovarian tissues. Raman spectral measurements were performed on fresh ovarian tissue samples from 17 ovarian cancer patients and 14 benign ovarian tumors. We preliminarily identified the Raman peaks in the measured ovarian tissue spectra and summarized their respective characteristic peaks, indicating that specific biomolecules changed among different groups, and their differences were analyzed. The conclusions suggested that the position of the characteristic peaks of Raman spectrum of the ovarian cancer tissues and benign ovarian tissues were different. The relative intensity of ovarian cancer tissue was higher than that of benign ovarian tissue at the 1004, 1155, 1446 cm−1 with phenylalanine, protein and lipids as characteristic peaks, and the difference were significant (P < 0.05). This exploratory work demonstrates that RS may be used as a detection method for screening benign and malignant ovarian tumors.

Chronic oxidative stress resulting from hyperlipidemia is thought to be a key pathogenic driver of pancreatic β-cell dysfunction in leading to the onset of type 2 diabetes mellitus (T2DM). Long non-coding RNAs (lncRNAs) have been increasingly recognized to regulate dysfunction within pancreatic β-cells in the context of T2DM. In the present study, we sought to comprehensively analyze the roles of lncRNAs in dysfunctional β-cells and mouse islets. Analyses of INS-1E cells were performed by RNA-seq and qRT-PCR after treating with or without 0.5 mM palmitate for 4 days, leading us to identify the novel lncRNA Eif4g2 (lncEif4g2) as a functional regulator within these cells. When we overexpressed lncEif4g2 in INS-1E β-cells and mouse islets, this was sufficient for the reversal of palmitate-mediated reductions in cell viability, insulin production, ATP production by mitochondria, and creation of intracellular reactive oxygen species (ROS) and the dysfunction of mouse islets, with nuclear factor erythroid 2 related factor 2 (Nrf2) activation also being observed. In contrast, when lncEif4g2 was knocked down this led INS-1E cells and mouse islets to become more sensitive to palmitate-induced dysfunction, with reduced Nrf2 nuclear translocation also being detected. When antioxidants were used to treat INS-1E cells and mouse islets, however, these negative effects were reversed. Additional functional analyses revealed lncEif4g2 to be capable of directly binding to miR-3074-5p in β-cells, with the expression of lncEif4g2 and miR-3074-5p being negatively correlated with one another. We further found that cAMP-responsive element binding-protein (CREB) was a miR-3074-5p target gene in these cells, thus at least in part serving as a functional mediator of the lncEif4g2/miR-3074-5p axis within dysfunctional β-cells. In summary, our results thus reveal that lncEif4g2 is able to indirectly regulate the expression of CREB via targeting miR-3074-5p in INS-1E cells and mouse islets, thereby leading to enhanced Nrf2 activation.

目的:研究核干细胞因子(Nucleostemin,NS)和组蛋白去乙酰化酶1(HDAC1)在卵巢肿瘤及正常卵巢组织中的表达,并分析其表达与临床指标的关系及两者间的表达相关性.方法:选择2010年至2017年我院卵巢石蜡标本60例,其中卵巢肿瘤50例,正常卵巢组织10例.应用免疫组化法检测NS与HDAC1的表达,并分析它们与年龄、肿瘤分期等临床指标的相关性.结果:在30例卵巢恶性肿瘤、10例卵巢交界性肿瘤、10例卵巢良性肿瘤组织中,NS表达的阳性率分别为93.3％、40％、20％,HDAC1的阳性率分别为90％、60％、20％.在正常卵巢组织中未见NS及HDAC1表达.在卵巢恶性肿瘤组中,NS和HDAC1的阳性表达率显著高于其他三组(P＜0.05),两者表达呈正相关(r=0.56,P＜0.05),且均与分化程度呈负相关(r=-0.76,P＜0.001;r=-0.53,P＜0.01),而与患者年龄、术前血清CA125水平、临床分期和病理类型无关.结论:NS和HDAC1倾向于卵巢恶性肿瘤中表达,且与卵巢恶性肿瘤的分化程度负相关.

目的 探讨紫草素对人乳腺癌MCF-7细胞凋亡的影响及其机制.方法 采用不同浓度(0.1、1、10μmol/L)的紫草素处理人乳腺癌MCF-7细胞24h,观察细胞活性、凋亡细胞比例及凋亡相关蛋白表达的变化.结果 紫草素能明显抑制MCF-7细胞增殖,促进细胞凋亡,升高Caspase-3、Cleaved Caspase-3、Caspase-9和Cleaved Caspase-9表达水平.结论 紫草素通过促进凋亡相关蛋白表达诱导MCF-7细胞凋亡,有望成为治疗乳腺癌的有效药物.

血小板升高与多种实体肿瘤的发生发展密切相关,研究表明14％-38％的恶性肿瘤患者伴有血小板升高.虽然目前国内外学者对于定义血小板升高的具体标准尚未完全统一,但大致范围在血小板计数大于220-400×109/L.大量的临床研究证实恶性肿瘤细胞可以分泌多种生长因子及细胞因子促进血小板升高,而升高的血小板又产生促进肿瘤细胞增殖、血管生长及转移的细胞因子.回顾相关文献在许多妇科恶性肿瘤研究中,除外阴癌外,治疗前的血小板升高多与疾病预后不良有关,由于血小板升高可以通过阻断血栓形成细胞因子来预防,因此对其评估在未来可能具有治疗意义.本文将就妇科恶性肿瘤与血小板升高的具体关联性进行探究.

The present study aimed to investigate the effect of long non-coding RNA (lncRNA) RP11-552M11.4 on cell proliferation, apoptosis, migration and invasion as well as its targeting genes in epithelial ovarian cancer (EOC) cells. LncRNA RP11-552M11.4 expression was detected in 67 tumor tissues and paired adjacent tissues obtained from EOC patients. lncRNA RP11-552M11.4 mimic/inhibitor plasmids were transferred into ovarian cancer cells (SKOV3, A-2780) and normal ovarian epithelial cells (IOSE80 cells). In addition, rescue experiment was carried out by transferring BRCA2 inhibitor&lncRNA RP11-552M11.4 inhibitor plasmids into SKOV3 and A-2780 cells. qPCR, western blot, CKK-8, Annexin V/propidium iodide (AV/PI), wound-healing and Matrigel invasion assays were carried out to detect RNA expression, protein expression, cell proliferation, apoptosis, migration, and invasion, respectively. LncRNA RP11-552M11.4 expression was elevated in tumor tissues compared with paired adjacent tissues and correlated with higher pathological grade, International Federation of Gynecology and Obstetrics stage and worse overall survival in EOC patients. LncRNA RP11-552M11.4 promoted SKOV3 cell proliferation, migration and invasion whereas it inhibited apoptosis. Rescue experiment and luciferase reporter assay showed that lncRNA RP11-552M11.4 regulated SKOV3 cells functions through binding BRCA2. Further experiments in A-2780 cells also validated that lncRNA RP11-552M11.4 induced A-2780 cell proliferation while repressing apoptosis by targeting BRCA2. In addition, upregulation of lncRNA RP11-552M11.4 increased IOSE80 cell proliferation, migration and invasion while decreasing apoptosis. In conclusion, lncRNA RP11-552M11.4 correlates with worse prognosis, and promotes cell proliferation, migration, invasion, and inhibits cell apoptosis by down-regulating BRCA2 in EOC.

OBJECTIVE:This study aims to evaluate the relationship between apoptosis and autophagy induced by resveratrol (Res) in SKOV3 human ovarian cancer cell lines.METHODS:The experiment was divided into four groups: normal control group, Res group, Res combined with autophagy inhibitor 3-methyladenine (Res+3-MA) group, and Z-VAD-FMK group. SKOV3 cells were cultured and treated with Res and 3-MA for 24 hours. The processing concentration of Res was screened out by the Cell Counting Kit-8 (CCK8) assay. The cell survival rate was measured by the CCK8 assay. The expression of bule-associated protein light chain 3 beta 2 (LC3-II) and Beclin-1 was detected using Western blot analysis. The percentages of apoptotic and autophagic cells were analyzed using flow cytometry.RESULTS:The cell survival rate significantly decreased as Res concentration increased, and the differences were statistically significant (P < 0.05). The processing concentration of Res was 25 μmol/L. After treatment with Res for 24 hours, the expression levels of autophagy-related protein LC3 and Beclin-l were significantly higher than in the other groups. Furthermore, the expression of LC3 and Beclin-l significantly declined in the Res+3-MA group compared with the Res group. However, the percentage of autophagic cells significantly decreased from 37.0% ± 4.24% to 6.1% ± 0.28%, and the percentage of apoptotic cells significantly increased from 24% ± 4.55% to 67.0% ± 4.3%; and the differences were statistically significant ( P < 0.05).CONCLUSION:Res can induce autophagy to inhibit apoptosis in tumor SKOV3 cells, and inhibition of Res+3-MA could not only enhance the effects of chemotherapy but also prevent normal cells from tumorigenesis.

The treatment of premenopausal patients with endometrial cancer has not yet been standardized,first of all,drug dosage,drug intake,treatment time and so on,there are no clear standards.Secondly,because of the high recurrence rate,is it unclear whether the patient needs to be removed after delivery.By reading a large number of literature and clinical prospective study,the main drug treatment is given priority to with low dose,treatment time is generally about 9-12 months.In addition to the traditional simple oral hormone therapy,in recent years,the treatment of LNG-IUS,the LNG-IUS and GnRHa combined therapy,hysteroscopic surgery and hormone combination therapy are gradually carried out.And through assisted reproductive technology,the success rate of pregnancy is increasing after treatment.Research shows that the treatment of premenopausal endometrial cancer is very promising at present,but a large number of clinical trials are needed to improve the treatment strategy.In this paper,by combining with clinical practice and the literature,we do a review about indication selection,pretreatment evaluation,treatment plan,curative effect evaluation,condition monitoring,and the problems that need to be faced after birth.

目的 探讨纽曼系统护理模式对子宫内膜癌患者子宫全切术后焦虑抑郁情绪的作用.方法 选取该院2014年10月至2015年8月因子宫内膜癌行子宫全切术的患者90例.随机分为对照组和试验组,对照组接受常规护理,试验组采用纽曼系统模式进行护理.通过一系列量表比较2组患者在入院时、术前后、出院时的焦虑情况和抑郁情况.结果 试验组和对照组的焦虑自评量表(SAS)和抑郁自评量表(SDS)评分在术前后和出院时的差异有统计学意义(P<0.05).临床症状自评量表(SCL-90)评分中的恐怖、躯体化、焦虑、抑郁、精神病性、人际关系等因子得分差异有统计学意义(P<0.05).结论 纽曼系统护理能显著降低子宫内膜癌患者行子宫全切术后的焦虑抑郁情绪,显著提高患者术后的生命质量和家庭辛福感.

Objectives:To discuss the effect of photodynamic therapy on the expression of macrophage migration inhibitory factor (MIF) of transplanted tumor in human cervical carcinoma Caski cells in nude mice.Methods:Nude mice of BALB/c were selected and given human cervical carcinoma Caski cells by subcutaneous injection,and the forty mice bearing tmnor criteria after 10d were divided into four groups according to the random digital table method,namely group A,B,C and D,with ten in each.The group A were chosen as the negative control,while the group B were given photodynamic therapy once,the group C were given photodynamic therapy for 3 times and the group D were given cisplatin for intraperitoneal injection.The tumor volume before treatment and at 2 weeks after treatment was compared,and the changes in body mass of nude mice,tumor volume and tumor mass and inhibition rates before and after treatment were compared,and the expressions of MIF of tumor tissues were detected by western-blot and immunohistochemical method and compared and analyzed.Results:The differences in the changes of body mass of nude mice,tumor volume and tumor mass between group B,C and D and group A were statistically significant (P ＜ 0.05),and the differences in the above indexes and the tumor inhibition rates between group C and D and group B were statistically significant (P ＜ 0.05),while that between group C and D was not statistically significant (P ＞ 0.05).The electron microscopic analysis showed that there were obvious vacuoles in the cytoplasm of the tumor cells in each group,and there were obvious necrosis foci in the clusters,and with the increase of the dose of photodynamic therapy,the more obvious the area of necrosis was.The MIF protein IOD values in the group B,C and D were significantly decreased compared with that in the group B (P ＜ 0.05),and the relative expression of protein MIF and IOD values in the group C and D were significantly decreased compared with those in the group B (P ＜ 0.05),while the differences in the relative expression of protein MIF and IOD values between the group C and group D were not statistically significant (P ＞ 0.05).Conclusion:The treatment effect of multiple photodynamic therapy on human cervical cancer Caski cells in nude mice is similar to that of cisplatin,and the expression level of MIF is significantly decreased.

[目的]了解乳腺癌病人自我超越和创伤应激障碍现状，并分析两者的相关性。[方法]采用一般资料问卷、自我超越量表和创伤后应激障碍筛查量表对487例乳腺癌病人进行调查。[结果]乳腺癌病人的自我超越得分为(39.64±8.32)分，创伤后应激障碍得分为(40.58±10.84)分；自我超越与创伤后应激障碍总分及各维度均呈负相关(P<0.05)。[结论]在制定乳腺癌病人治疗和康复计划时，应重点关注病人自我接纳和寻找生命意义等自我超越方面的问题，减少应激障碍的发生。

复发性卵巢癌的高发率及致死率一直是临床上的难题.根据复发性卵巢癌的定义、发病因素、诊断方法来不断探究对其有效的治疗方法是临床亟待解决的难题,结合患者的个人情况,是否行二次手术、如何确定化疗方案等问题仍然在不断地探索和实践中.另外,治疗新领域的开拓,如生物治疗、分子靶向治疗等新兴治疗方法已普遍被人们所接受,并积极运用于临床实践当中,已取得较好的治疗效果.

Objective:To investigate the effect and mechanism of EGCG on human ovarian cancer SKOV3 cells′apoptosis. Methods:SKOV3 cells were divided into four groups. Negative control group:cultured with normal culture medium;EGCG low dose group:cultured with 1μmol/L EGCG;EGCG middle dose group:cultured with 10μmol/L EGCG;EGCG high dose group:cultured with 100μmol/L EGCG. Cell proliferation inhibition rate of each group of SKOV3 cells were test by MTT assay, nuclei apoptosis were checked by Hoechs staine, cells morphology were investigated by electron microscope, Caspase-3 expression was detected by Western-blot. Results:Cell proliferation inhibition test results showed that the inhibition rate of EGCG low, medium and high concentration group on SKOV3 cells was (81.33±3.71)%, (67.00±7.21)%and (54.67±3.84)%, the difference was statistically significant (P<0.05) compared with the negative control group (101.00 ±3.06)%. Hoechst33258 staining results showed that, apoptosis cell percentage of EGCG low, medium and high concentration group was (16.77 ±2.48)%, (24.33±3.70)%and (39.67±4.11)%, the difference was statistically significant (P<0.05) compared with the negative control group [(2.00±1.45)%]. Electron microscopy showed that with the concentration of EGCG elevated, the damage on ultrastructure of SKOV3 cell became clear. In addition, EGCG could raised Caspase-3 expression levels. Conclusions:EGCG induced ovarian cancer SKOV3 cells apoptosis by enhancing the expression of Caspase-3 gene.

MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that regulate gene expression at post-transcriptional level. Increasing evidences show aberrant expression of miRNAs in varieties of diseases. Targeting the dysregulated miRNAs with small molecule drugs has become a novel therapy for many human diseases, especially cancer. Here, we proposed a novel computational approach to identify associations between small molecules and miRNAs based on functional similarity of differentially expressed genes. At the significance level of p < 0.01, we constructed the small molecule and miRNA functional similarity network involving 111 small molecules and 20 miRNAs. Moreover, we also predicted associations between drugs and diseases through integrating our identified small molecule-miRNA associations with experimentally validated disease related miRNAs. As a result, we identified 2265 associations between FDA approved drugs and diseases, in which ~35% associations have been validated by comprehensive literature reviews. For breast cancer, we identified 19 potential drugs, in which 12 drugs were supported by previous studies. In addition, we performed survival analysis for the patients from TCGA and GEO database, which indicated that the associated miRNAs of 4 drugs might be good prognosis markers in breast cancer. Collectively, this study proposed a novel approach to predict small molecule and miRNA associations based on functional similarity, which may pave a new way for miRNA-targeted therapy and drug repositioning.

BACKGROUND:Breast cancer is the most common incident form of cancer in women including different subtypes. Cancer stem cells (CSCs) have been confirmed to exist in breast cancer. But the research on the origin of breast cancer subtype stem cells (BCSSCs) is still inadequate.METHODS:We identified the putative origin cells of BCSSCs through comparing gene signatures between BCSSCs and normal mammary cells from multiple perspectives: common signature, expression consistency, functional similarity and shortest path length. First, the potential origin cells were ranked according to these measures separately. Then Q statistic was employed to combine all rank lists into a unique list for each subtype, to prioritize the origin cells for each BCSSC. Next, we identified origin-related gene modules through integrating functional interaction network with differentially expressed genes. Finally, transcription factors of significant gene modules were predicted by MatchTM.RESULTS:The results showed that Luminal A CSC was most relevant to luminal progenitor cell or mature luminal cell; luminal B and HER2 CSC were most relevant to bipotent-enriched progenitor cell; basal-like CSC was most relevant to bipotent-enriched progenitor cell or mature luminal cell. Network modules analysis revealed genes related to mitochondrial respiratory chain (MRC) were significantly dysregulated during the origin of luminal B CSC. In addition, SOX10 emerged as a key regulator of MRC.CONCLUSIONS:Our study supports substantive evidence for the possible origin of four kinds of BCSSCs. Dysfunction of MRC may contribute to the origin of luminal B CSC. These findings may have important implications to treat and prevent breast cancer.

Prostate cancer (PC) is one of the most common solid tumors in men. However, the molecular mechanism of PC remains unclear. Numerous studies have demonstrated that long noncoding RNA (lncRNA) can act as microRNA (miRNA) sponge, one type of competing endogenous RNAs (ceRNAs), which offers a novel viewpoint to elucidate the mechanisms of PC. Here, we proposed an integrative systems biology approach to infer the gain and loss of ceRNAs in PC. First, we re-annotated exon microarray data to obtain lncRNA expression profiles of PC. Second, by integrating mRNA and miRNA expression, as well as miRNA targets, we constructed lncRNA-miRNA-mRNA ceRNA networks in cancer and normal samples. The lncRNAs in these two ceRNA networks tended to have a longer transcript length and cover more exons than the lncRNAs not involved in ceRNA networks. Next, we further extracted the gain and loss ceRNA networks in PC. We found that the gain ceRNAs in PC participated in cell cycle, and the loss ceRNAs in PC were associated with metabolism. We also identified potential prognostic ceRNA pairs such as MALAT1-EGR2 and MEG3-AQP3. Finally, we inferred a novel mechanism of known drugs, such as cisplatin, for the treatment of PC through gain and loss ceRNA networks. The potential drugs such as 1,2,6-tri-O-galloyl-beta-D-glucopyranose (TGGP) could modulate lncRNA-mRNA competing relationships, which may uncover new strategy for treating PC. In summary, we systematically investigated the gain and loss of ceRNAs in PC, which may prove useful for identifying potential biomarkers and therapeutics for PC.

Hyaluronic acid binding protein 1 (HABP1/gC1qR/p32), a ubiquitous multifunctional protein belonging to the hyaladherin family, has been implicated in the tumorigenesis, progression, invasion, and metastasis of several malignant tumors. However, the role of HABP1 in endometrial cancer has not yet been studied. This study aimed to detect the expression of HABP1 in endometrial cancer and explore its role in the clinicopathological features and prognosis of endometrial cancer. We analyzed HABP1 expression by immunohistochemistry in 188 endometrial cancer specimens, 43 benign endometrial lesion specimens, and 41 normal endometrium specimens and assessed using Western blot analysis. Statistical analysis showed that HABP1 was overexpressed in endometrial cancer and benign endometrial lesion compared with normal endometrium ( P < 0.001 and P = 0.012, respectively). In addition, HABP1 expression was significantly higher in endometrial cancer than in benign endometrial lesion ( P < 0.001). High HABP1 expression was significantly associated with advanced International Federation of Gynecology and Obstetrics stage ( P = 0.019), higher histologic grade ( P < 0.001), deep myometrial invasion ( P = 0.013), lymphovascular space invasion ( P = 0.010), lymph node metastasis ( P = 0.015), and recurrence ( P = 0.009). Patients with high HABP1 expression had a poorer overall survival (OS) and disease-free survival (DFS) than patients with low HABP1 expression ( P = 0.015 and P = 0.012, respectively). Multivariate Cox regression analysis showed that the HABP1 expression status was an independent prognostic factor of OS and DFS ( P = 0.025 and P = 0.022, respectively) in patients with endometrial cancer. Our results indicated that overexpression of HABP1 may serve as a new biomarker to predict the progression and prognosis of endometrial cancer.